In an in vivo mouse model of DEN-induced HCC, administration of CASE at doses of 60, 120, or 240 mg/kg for 12 or 16 weeks suppressed p-ERK, p-JNK, and p-p38 expression. This evidence concerns the gene MAPK1 and hepatocellular carcinoma.